etrasimod + Placebo

Phase 2Recruiting

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Pouchitis

Conditions

Pouchitis

Trial Timeline

Mar 1, 2026 → Feb 6, 2030

NCT ID

NCT07486921

About etrasimod + Placebo

etrasimod + Placebo is a phase 2 stage product being developed by Pfizer for Pouchitis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07486921. Target conditions include Pouchitis.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (4)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07486921	Phase 2	Recruiting	Mar 1, 2026	Feb 6, 2030	Pouchitis
NCT05732454	Phase 2/3	Terminated	Jan 18, 2023	Apr 29, 2024	Atopic Dermatitis
NCT04607837	Phase 2	Completed	Apr 12, 2021	Jun 19, 2024	Ulcerative Colitis
NCT04706793	Phase 3	Completed	Dec 25, 2020	Aug 3, 2022	Ulcerative Colitis

Competing Products

3 competing products in Pouchitis

See all competitors

Product	Company	Stage	Hype Score
Mirikizumab - Intravenous (IV) + Mirikizumab - Subcutaneous (SC)	Eli Lilly	Approved	85
Liraglutide Pen Injector + Placebo Pen Injector	Novo Nordisk	Phase 2	51
Rifaximin 550 MG Oral Tablet [XIFAXAN]	Bausch Health	Approved	80

Other Products from Pfizer